Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer

Hellenic Cooperative Oncology Group

Status: Completed

Conditions: Gastric Cancer Stage IV; Ramucirumab Paclitaxel; Second-line Treatment

Treatments: Drug: Paclitaxel and ramucirumab

Study type: Observational

Funder types: Other

Identifiers

NCT06666582

RE721

Details and patient eligibility

About

Our aim was to evaluate whether second-line treatment with paclitaxel and ramucirumab was associated with improved clinical outcomes compared to other available therapies. This study involved real-world data collection, focusing on the safety and efficacy of therapeutic combinations, administered to patients with pretreated advanced gastric cancer in the Oncology Departments affiliated with the Hellenic Cooperative Oncology Group (HeCOG).

Enrollment: 185 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with unresectable or metastatic, locally advanced adenocarcinoma of the stomach, gastroesophageal junction, or distal esophagus
• Treated at Departments of Medical Oncology affiliated with the Hellenic Cooperative Oncology Group (HeCOG)
• Second-line treatment for advanced disease
• Treatment for at least two months of second-line treatment.

Exclusion criteria

• Lack of informed consent in case the patient was alive

Trial design

185 participants in 2 patient groups

Patients who received paclitaxel - ramucirumab as second-line treatment

Description:

Patients with unresectable or metastatic, locally advanced adenocarcinoma of the stomach, gastroesophageal junction, or distal esophagus who had been treated at Departments of Medical Oncology affiliated with the Hellenic Cooperative Oncology Group (HeCOG). All patients had received second-line treatment for advanced disease with paclitaxel and ramucirumab, for at least two months.

Treatment:

Drug: Paclitaxel and ramucirumab

Patients who received other regimens as second-line treatment

Description:

patients with unresectable or metastatic, locally advanced adenocarcinoma of the stomach, gastroesophageal junction, or distal esophagus who had been treated at Departments of Medical Oncology affiliated with the Hellenic Cooperative Oncology Group (HeCOG). All patients had received second-line treatment for advanced disease based on international/national guidelines, except from paclitaxel and ramucirumab. All other regimens, combinations of drugs as well as monotherapy, were accepted. Patients were included in the analysis if they have received at least two months of second-line treatment.

Treatment:

Drug: Paclitaxel and ramucirumab